GR990100373A - Stable apomorphine solution formulations - Google Patents

Stable apomorphine solution formulations

Info

Publication number
GR990100373A
GR990100373A GR990100373A GR990100373A GR990100373A GR 990100373 A GR990100373 A GR 990100373A GR 990100373 A GR990100373 A GR 990100373A GR 990100373 A GR990100373 A GR 990100373A GR 990100373 A GR990100373 A GR 990100373A
Authority
GR
Greece
Prior art keywords
stable
solution formulations
apomorphine solution
apomorphine
solution
Prior art date
Application number
GR990100373A
Other languages
Greek (el)
Inventor
Eva Bernini
Paolo Chiesi
Gaetano Brambilla
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of GR990100373A publication Critical patent/GR990100373A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A formulation containing apomorphine hydrochloric hemihydrate in aqueous solution in combination with excipients, said solution being stable for at least two years up to 25 degrees C and able to warrant low microbial count after opening and during use.
GR990100373A 1998-10-30 1999-10-27 Stable apomorphine solution formulations GR990100373A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002331A IT1303684B1 (en) 1998-10-30 1998-10-30 FORMULATIONS OF APOMORPHINE IN SOLUTION STABLE OVER TIME.

Publications (1)

Publication Number Publication Date
GR990100373A true GR990100373A (en) 2000-06-30

Family

ID=11380970

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990100373A GR990100373A (en) 1998-10-30 1999-10-27 Stable apomorphine solution formulations

Country Status (6)

Country Link
BR (1) BR9905305A (en)
ES (1) ES2156763B1 (en)
FR (1) FR2785188B1 (en)
GB (1) GB2343376B (en)
GR (1) GR990100373A (en)
IT (1) IT1303684B1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770376B2 (en) * 1999-09-29 2004-02-19 Procter & Gamble Company, The Compositions having improved stability
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
CN104349768B (en) 2012-06-05 2017-11-07 纽罗德姆有限公司 Composition comprising apomorphine and organic acid and application thereof
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROOKES RW, ET AL.: "An investigation of the stability of apomorphine injection upon sterilisation", THE PHARMACEUTICAL JOURNAL, vol. 247, 1991, ISSN: 0031-6873, pages R11 - R11A, XP000925015 *
CHEMICAL ABSTRACTS, vol. 102, no. 14, 8 April 1985, Columbus, Ohio, US; abstract no. 119532, XP002145215 *
ESSINK AW AND RUTTEN WJ: "Bereiding van apomorfine neusspray", PHARMACEUTISCH WEEKBLAD, vol. 126, no. 44, 1991, ISSN: 0031-6911, pages 1113 - 1114, XP000925003 *
LUNDGREN P AND LANDERSJÖ L: "Stability and stabilization of apomorphine hydrochloride in aqueous solutions", ACTA PHARMACEUTICA SUECICA, vol. 7, no. 2, 1970, ISSN: 0001-6675, pages 133 - 148, XP000924990 *
PANDOLFO V, ET AL.: "Stabilità di formulazioni parenterali di apomorfina", BOLLETINO CHIMICO FARMACEUTICO, vol. 123, no. 9, 1984, ISSN: 0006-6648, pages 449 - 452, XP000900674 *

Also Published As

Publication number Publication date
FR2785188A1 (en) 2000-05-05
ES2156763A1 (en) 2001-07-01
ES2156763B1 (en) 2002-03-01
FR2785188B1 (en) 2004-10-29
IT1303684B1 (en) 2001-02-23
BR9905305A (en) 2001-03-20
GB2343376B (en) 2003-12-31
ITMI982331A1 (en) 2000-04-30
GB2343376A (en) 2000-05-10
GB9925602D0 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
AP2003002755A0 (en) Guanidinobenzamides as mc4-r agonists
HK1043064B (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
AU2001237051A1 (en) Cone-beam computerized tomography with a flat-panel imager
ZA200200695B (en) Mutilin derivatives and their use as antibacterials.
AU4990200A (en) Fabric for use in prosthetics
IL155263A0 (en) Pharmaceutical solutions of modafinil compounds
CA2429639A1 (en) Stable azithromycin monohydrate
IL161235A0 (en) Fsh composition, its preparation and use
ZA200108718B (en) Thiazolidinedione derivative and its use as antidiabetic.
GB0026467D0 (en) Compound, composition and use
GR990100373A (en) Stable apomorphine solution formulations
MXPA03001826A (en) Arylpiperazine derivatives and their use as psychotropic agents.
GB9905663D0 (en) Iodine preparation composition
HK1045151A1 (en) Thiazolidinedione derivative and its use as antidiabetic.
HUP0102226A3 (en) Hyperforin derivatives, the use thereof and formulations containing them
IL156174A0 (en) 1,2,4-oxadizaole derivatives as hppar alpha agonists
HK1045304A1 (en) Thiazolidinedione derivative and its use as antidiabetic.
EP1052189A3 (en) Tablet dispenser
GB0005301D0 (en) Compound, composition and use
ES2137139A1 (en) Use of an association of chlorhexidine digluconate and a zinc salt.
陈宣荣 English Ambiguity and Disambiguation in English-Chinese Machine Translation
AU2002235767A1 (en) Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
高熊 Not Half the Man I Used to Be
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors
IL131156A0 (en) 4-Aminoalkyl-1,3-dihydrobenzoimidazol-2-one derivatives their preparation and their use as dopamine autoreceptor (d2) agonists

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees

Effective date: 20120503